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Neurobiology of Disease
Astrocytic LRP1 Mediates Brain A Clearance and Impacts
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Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, and 3Fujian Provincial Key Laboratory of
Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, 361102 China
Accumulation and deposition of amyloid- (A) in the brain represent an early and perhaps necessary step in the pathogenesis of
Alzheimer’s disease (AD). A accumulation leads to the formation of A aggregates, which may directly and indirectly lead to eventual
neurodegeneration. While A production is accelerated in many familial forms of early-onset AD, increasing evidence indicates that
impaired clearance of A is more evident in late-onset AD. To uncover the mechanisms underlying impaired A clearance in AD, we
examined the role of low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. Although LRP1 has been shown to play
critical roles in brain Ametabolism in neurons and vascular mural cells, its role in astrocytes, the most abundant cell type in the brain
responsible formaintaining neuronal homeostasis, remains unclear. Here, we show that astrocytic LRP1 plays a critical role in brain A
clearance. LRP1 knockdown in primary astrocytes resulted in decreased cellular A uptake and degradation. In addition, silencing of
LRP1 inastrocytes led todownregulationof severalmajorA-degrading enzymes, includingmatrixmetalloproteasesMMP2,MMP9, and
insulin-degrading enzyme. More important, conditional knock-out of the Lrp1 gene in astrocytes in the background of APP/PS1 mice
impairedbrainA clearance, exacerbatedA accumulation, andaccelerated amyloidplaquedepositionwithout affecting its production.
Together, our resultsdemonstrate that astrocyticLRP1plays an important role inAmetabolismand that restoringLRP1expressionand
function in the brain could be an effective strategy to facilitate A clearance and counter amyloid pathology in AD.
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Introduction
Astrocytes, as scaffolds supporting brain structural integrity, repre-
sent one of the major cell types regulating diverse brain functions.
Through their bidirectional interactions with neurons, astrocytes
actively regulate neuronal signaling pathways in addition to main-
taining synaptic homeostasis by modulating the extracellular ionic
environment and providing nutrients/metabolites for neurons
(Wang and Bordey, 2008; Sofroniew and Vinters, 2010; Osborn et
al., 2016). Astrocytes also significantly contribute to immune re-
sponses as evidenced by their coupling with microglia in neurode-
generative diseases, including Alzheimer’s disease (AD) (Sofroniew
and Vinters, 2010; Meraz-Ríos et al., 2013). Indeed, astrogliosis ac-
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Significance Statement
Astrocytes represent amajor cell type regulatingbrainhomeostasis; however, their roles inbrain clearance of amyloid- (A) and
underlying mechanism are not clear. In this study, we used both cellular models and conditional knock-out mouse models to
address the role of a critical A receptor, the low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. We found
that LRP1 in astrocytes plays a critical role in brain A clearance by modulating several A-degrading enzymes and cellular
degradation pathways. Our results establish a critical role of astrocytic LRP1 in brain A clearance and shed light on specific A
clearance pathways that may help to establish new targets for AD prevention and therapy.
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companied by the upregulation of GFAP and hypertrophic pro-
cesses of astrocytes surrounding senile plaques are pathological
hallmark of AD (Osborn et al., 2016).
AD is characterized by progressive neurodegeneration, result-
ing in dementia (Alzheimer’sAssociation, 2015). The accumula-
tion and deposition of amyloid- (A) peptides cleaved from
amyloid precursor protein (APP) in the brain likely are central in
ADdevelopment andprogression (Hardy and Selkoe, 2002; Blen-
now et al., 2006; Zheng andKoo, 2011). In ADbrains, astrogliosis
has been shown to increase linearly with disease progression,
which negatively correlates with cortical thickness (Serrano-Pozo
et al., 2011). On the other hand, attenuation of astrocyte activa-
tion by deleting GFAP and vimentin exacerbates amyloid plaque
pathogenesis in amyloid model mice (Kraft et al., 2013), suggest-
ing that astrocytesmay play an important role in Ametabolism.
Astrocyte-regulated A metabolism involves multiple mech-
anisms (Wyss-Coray et al., 2003; Nielsen et al., 2010), with the
low-density lipoprotein receptor (LDLR) family members, spe-
cifically LDLR-related protein 1 (LRP1), likely playing a critical
role. LRP1, a multiligand single transmembrane receptor, has
been shown to regulate brain Ametabolism (Kanekiyo and Bu,
2014), whereas its antagonist, receptor-associated protein (RAP),
significantly suppresses A degradation by astrocytes (Koisti-
naho et al., 2004). Conditional deletion of the Lrp1 gene in neu-
rons (Kanekiyo et al., 2013), vascularmural cells (Kanekiyo et al.,
2012), and endothelial cells (Storck et al., 2016) aggravates A
deposition in amyloid model mice. Despite the fact that LRP1 is
abundantly expressed in astrocytes, the contribution of LRP1 to
A metabolism in astrocytes has not been well studied in vivo.
Here, using cellular and conditional knock-out mouse models,
we show that LRP1 deficiency in astrocytes disturbed Ametab-
olism through several pathways, leading to exacerbated amyloid
pathology.
Materials andMethods
Animal and preparation of brain homogenates. All animal procedures
were approved by the Institutional Animal Care and Use Committee at
Mayo Clinic and in accordance with the regulations of the American
Association for the Accreditation of Laboratory Animal Care. Astrocyte-
specific Lrp1-KOmice (aLrp1 /) were generated by breeding the Lrp1
floxedmice (Rohlmann et al., 1998) with GFAP-driven Cre recombinase
mice (obtained fromNCIMouse Repository) (Bajenaru et al., 2002), and
further bred into the background of APPSWE/PS1E9 amyloid mouse
model (Jankowsky et al., 2004) (hereafter referred to as APP/PS1). Lit-
termates (including bothmale and female mice) of control APP/PS1 and
APP/PS1 mice lacking LRP1 in astrocytes (APP/PS1; aLrp1/) were
used. In a separate experiment, littermates of control and astrocytic LRP1
knock-out mice (aLrp1/) without the APP/PS1 background were
used. Brain tissues were dissected and kept frozen at80°C until further
analysis. Some brain tissues were fixed in 10% neutralized formalin for
histological analysis. Mouse brain tissues for A analysis were processed
through sequential extraction as described previously (Liu et al., 2014).
Cell culture, lentivirus-delivered RNA interference, and A ELISA anal-
ysis.Neonatalmouse primary astrocytes and adultmouse astrocytes were
prepared as described previously (Koistinaho et al., 2004; Zhao et al.,
2014). LRP1-specific shRNAs were purchased from Sigma, and lentivi-
ruses were produced in the Viral Vectors Core facility at Washington
University School of Medicine. In brief, 293T cells were transfected with
pLKO.1-derived constructs together with the pHR8.2 and pCMV-
VSV-G packaging systems as previously described (Stewart et al., 2003).
Nontarget shRNA was used as a control. A levels in the mouse brain
lysates were determined by ELISA (Youmans et al., 2011; Das et al., 2012)
with end-specific mAb 2.1.3 (human Ax-42 specific) and mAb 13.1.1
(human Ax-40 specific) for capture and HRP-conjugated mAb Ab5
(human A1–16 specific) for detection. The ELISAs were developed us-
ing Super Slow ELISA TMB (Sigma).
FACS-based internalization and binding assays, and A degradation
assay. A42 and FAM-A42 were purchased from AnaSpec, and the
experiments were performed as described previously (Kanekiyo et al.,
2011). Cells were incubated with FAM-A42 (500 nM) at 37°C for differ-
ent period of time in DMEM with 10% FBS for internalization assay.
Cells were removed from the plate using Cell Dissociation Solution
(Sigma) and then washed and resuspended in PBS containing 1.5% FBS,
1% sodium azide, and 1% PFA. Cells were analyzed for fluorescence on a
BDFACSCaliburmachine (BDBiosciences).Unstained cells without any
exposure to fluorescence were used as a control for background fluores-
cence. For binding assays, cells were incubated with FAM-A42 (200 or
500 nM) at 4°C for 2 h, suspended by cell dissociation solution, and
subjected to FACS analysis. For A degradation assay, cells were allowed
to internalize A42 (1 M) for 2 h at 37°C. Cultures were washed and
incubated inmedium lacking A42 for an additional 6 h. Cells were then
dissolved in guanidine in 50mMTris-HCl, pH8.0, and cell-associatedA
levels were analyzed by ELISA.
Immunohistochemical and immunofluorescent staining. Paraffin-
embedded sections were immunostained using pan-A (A 33.1.1; hu-
man A 1–16 specific), anti-GFAP (BioGenex), and anti-ionized
calcium-binding adaptor molecule 1 (Iba-1) (Wako) antibodies (Liu et
al., 2016). Immunohistochemically stained sections were captured using
the ImageScope AT2 image scanner (Aperio Technologies) and analyzed
using the ImageScope software. The immunoreactivities of GFAP and
Iba-1 staining in the hippocampus were calculated using the Positive
Pixel Count Algorithm available with the ImageScope software (Aperio
Technologies). For double immunostaining, deparaffinized sections
were preincubated with citrate buffer (10 mM sodium citrate buffer with
0.05%Tween 20, pH 6.0) at 95°C for 20min. They were incubated at 4°C
overnight with a rabbit anti-LRP1 antibody (Bu et al., 1995) and amouse
anti-NeuN antibody (Millipore) or a mouse anti-GFAP antibody (Milli-
pore), followed by Alexa488- or Alexa568-conjugated secondary anti-
bodies (Invitrogen) for 2 h at room temperature. The images were
captured by confocal laser-scanning fluorescence microscopy (model
LSM510 invert; Carl Zeiss) (Fu et al., 2016).
In vivo microdialysis. To assess interstitial fluid (ISF) A in the hip-
pocampus of awake, freely moving APP/PS1 and APP/PS1; aLrp1/
mice, in vivo microdialysis was performed as previously described
(Cirrito et al., 2011; Liu et al., 2016). Briefly, under isoflurane volatile
anesthetic, guide cannula (BR style; Bioanalytical Systems) were ce-
mented into the hippocampus (3.1mmbehind bregma, 2.5mm lateral to
midline, and 1.2 mm below dura at a 12° angle). A microdialysis probe
(38 kDa molecular weight cutoff membrane; Bioanalytical Systems) was
inserted through the guide cannula into the brain. ACSF (1.3 mM CaCl2,
1.2 mM MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3, and 122
mMNaCl, pH 7.4) containing 4%BSA (Sigma) filtered through a 0.1m
membrane was used as microdialysis perfusion buffer. Flow rate was a
constant 1.0l/min. Samples were collected every 60–90min overnight,
which gets through the 4–6 h recovery period, and the mean concentra-
tion of A over the 6 h preceding treatment was defined as basal levels of
ISF A. Sample were collected through a refrigerated fraction collector
and assessed for A40 by ELISA as described previously (Cirrito et al.,
2011).
Western blotting. Samples were homogenized and incubated in TBS
containing 1% TX-100, supplemented with protease inhibitor. The de-
tailed procedures were performed as previously described (Liu et al.,
2015). The following antibodies were used in this study: in-house anti-
LRP1 antibody (Bu et al., 1995), anti-GFAP (Millipore), 6E10 (Covance)
for total APP, anti-sAPP (IBL-America), anti-human sAPP (IBL-
America), aquaporin-4 (AQP-4; Millipore), and anti--actin (Sigma)
antibodies.
RNA isolation and real-time PCR analysis. Total RNA was isolated by
using Trizol (QIAGEN), RNeasy Mini Kit (QIAGEN) and subjected to
DNase I digestion to remove contaminating genomic DNA. Total RNA
was dissolved in nuclease-free water and stored at80°C. Reverse tran-
scription was performed using a SuperScript III reverse transcriptase
(Invitrogen). Primer sequences were as previously described (Liu et al.,
2016). The set of actin primers was used as an internal control for each
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specific gene amplification. The relative expressions were quantified and
analyzed by using Bio-Rad iCycler.
Statistical analysis. All quantified data represent an average of sam-
ples. Statistical significance was determined by two-tailed Student’s t
test or ANOVA with a Tukey’s post-test, and p 0.05 was considered
significant.
Results
LRP1 regulates Ametabolism in astrocytes
To determine the role of astrocytic LRP1 in Ametabolism, we first
examined whether LRP1 downregulation in astrocytes impacts cel-
lular A uptake. Using lentiviral-mediated control or LRP1 shRNA,
we successfully knocked downLRP1 inmouse primary astrocytes as
confirmed byWestern blot (Fig. 1A). Control or LRP1-knockdown
(KD) astrocytes were incubatedwith 500 nMFAM-labeledA42 for
1 or 2 h at 37°C, and cell-associated A was assessed by FACS. We
found that A42 uptake in LRP1-KD cells was significantly reduced
comparedwith control cells following incubationwithA42 for 1 h,
whereas this effectwasmoreprominent after 2h treatment (Fig. 1B).
To investigatewhether LRP1mediates the binding ofA42 to astro-
cytes, primary astrocytes were incubated with different concentra-
tions of FAM-A42 for 2 h at 4°C to prevent cellular uptake. We
found that downregulation of LRP1 did not have a significant effect
onA42binding to the cell surface of astrocytes as assessed by FACS
(Fig. 1C). To determine whether LRP1mediates the degradation of
A, primary astrocytes were incubated with A42 for 2 h at 37°C.
The A in themediumwas then removed, and the fate of A in the
cells was chased for 6 h. Cell-associated A42 was cleared following
6hof incubation in both control andLRP1-KDastrocytes (Fig. 1D).
However, A was cleared to a lesser extent in LRP1-KD astrocytes
comparedwithcontrol cells (Fig. 1E).These resultsdemonstrate that
LRP1 regulates the uptake and subsequent degradation of A in
astrocytes.
To investigate whether LRP1 modulates A metabolism
through extracellular A-degrading proteases, such as insulin-
degrading enzyme (IDE) (Leissring et al., 2003) and matrix met-
alloproteinases (MMPs) (Backstrom et al., 1996), we evaluated
the levels of thesemajor enzymes following LRP1 knockdown.Of
note, previous studies demonstrated that MMP2 and MMP9 ex-
pressed by astrocytes mediate extracellular A catabolism (Yin et
al., 2006), and LRP1 regulates MMP2 and MMP9 expression in
glioblastomas cells (Song et al., 2009). Upon lentiviral-mediated
knockdown of LRP1 expression by70% (Fig. 2A,B), we found
that the levels of IDE, MMP2, and MMP9 were significantly re-
duced (Fig. 2C,D). As such, LRP1 might also affect extracellular
degradation of A through the modulation of these degrading
enzymes.
Conditional knock-out of Lrp1 in astrocytes exacerbates
A deposition in APP/PS1 amyloid model mice
Toexamine the effect of astrocytic LRP1deletiononAmetabolism
in vivo, we conditionally disrupted the expressionof theLrp1 gene in
Figure 1. LRP1 mediates A uptake and degradation in primary astrocytes. A, Mouse pri-
mary astrocytes were transduced with lentiviral mediated control or LRP1 shRNA and were
analyzed 48 h after transfection. Western blotting showed that LRP1 expression was signifi-
cantly downregulated in primary astrocytes. **p 0.01 (two-tailed Student’s t test). B, Pri-
mary astrocyteswith orwithout LRP1 knockdownwere incubatedwith FAM-A42 (500 nM) for
1 or 2 h at 37°C, and the cell-associated A42 was analyzed by FACS. Representative results of
five independent experiments performed in triplicate are shown. **p  0.01 (two-way
ANOVA). C, Primary astrocytes with or without LRP1 knockdown were incubated with FAM-
A42 (200 or 500 nM) for 2 h at 4°C and analyzed by FACS. Representative results from three
independent experiments performed in triplicate are shown.D, Control and LRP1-KDastrocytes
were allowed to internalize A42 (1 M) for 2 h at 37°C (gray bars); parallel cultures were
washed and incubated for an additional 6 h inmedium lacking A42 (black bars) and analyzed
by ELISA. *p 0.05 (two-way ANOVA). **p 0.01 (two-way ANOVA). E, The decrease of
internalized A is estimated as cellular clearance. Data aremean SD. *p 0.05 (two-tailed
Student’s t test).
Figure 2. LRP1 downregulation in astrocytes suppresses the expression of major A de-
grading enzymes. A, B, LRP1 was significantly knocked down in primary astrocytes as assessed
byWestern blot and real-time PCR. Data are mean SEM. **p 0.01. C, D, The mRNA levels
of IDE, MMP2, and MMP9 in control and LRP1-KD primary astrocytes examined by real-time
PCR. Representative results from three independent experiments performed in quadruplicate
are shown. Data are mean SEM. *p 0.05 (two-tailed Student’s t test).
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astrocytes by crossing Lrp1flox/flox mice with GFAP-Cre mice (Baje-
naru et al., 2002), and further bred thesemice to the APP/PS1 amy-
loid mouse model (Jankowsky et al., 2004). To confirm deletion of
LRP1 in astrocytes, we performed immunofluorescent staining for
LRP1 and GFAP in adult astrocyte cultures derived from control
APP/PS1 and APP/PS1 mice lacking LRP1 in astrocytes (APP/PS1;
aLrp1/). We found the LRP1 signal was significantly diminished
in GFAP-positive astrocytes (Fig. 3A). Western blot analysis also
revealed significantly reduced levels of LRP1 in cortex and hip-
pocampus of APP/PS1; aLrp1/ mice compared with APP/PS1
mice (Fig. 3B), consistent with the notion that LRP1 is depleted in
astrocytes. The remaining LRP1 expression in APP/PS1; aLrp1/
mice likely represents those in neurons and in cells composed of
cerebrovasculature. Astrocytic LRP1 deletion did not affect brain
apolipoprotein E (apoE) levels in both cortex and hippocampus
(Fig. 3B), whereas our previous study showed that neuronal LRP1
knock-out results in increased apoE (Liu et al., 2007), thus differen-
tiating the effects of astrocytic and neuronal LRP1 deletion. To fur-
ther confirm the specificity of LRP1 deletion, the brain tissues
obtained from 12-month-old APP/PS1 and APP/PS1; aLrp1/
mice were stained with an LRP1-specific antibody together with as-
trocyte-specific (GFAP) and neuron-specific (NeuN) markers. In
both cortex and hippocampus of APP/PS1 mice, LRP1 was abun-
dantly expressed in neurons and astrocytes, whereas LRP1 in APP/
PS1; aLrp1/mice was specifically deleted in astrocytes (Fig. 3C).
Importantly, immunohistochemical staining revealed that the amy-
loid plaque deposition in APP/PS1; aLrp1/mice was significantly
higher than that of control APP/PS1 mice at 12 months of age (Fig.
4A). Inaddition, solubleAconcentrationswere significantlyhigher
in APP/PS1; aLrp1/ mice than in APP/PS1 mice (Fig. 4B,C), as
assessedbyELISA following fractionationof cortical andhippocam-
pal brain tissues into TBS-soluble, detergent-soluble, and insoluble
(guanidine-HCl,GDN) fractions (Youmans et al., 2011).Consistent
with increased amyloid deposition, the concentrations of insoluble
A40 and A42 in guanidine fractions were increased in the cortex
and hippocampus of APP/PS1; aLrp1/mice (Fig. 4B,C), suggest-
ing that astrocytic LRP1 plays an important role in regulating amy-
loid deposition.
LRP1 deletion in astrocytes suppresses A clearance without
affecting A production in amyloid model mice
To determine whether astrocytic LRP1 affects Ametabolism in
vivo, we firstmeasured ISFA concentration in the hippocampus
of APP/PS1 and APP/PS1; aLrp1/ mice at 3–4 months of age
using in vivo microdialysis. Soluble A found in ISF, which is
exchangeable across a dialysis membrane, significantly correlates
with total soluble A in brain extracellular pools (Cirrito et al.,
2003). Baseline concentrations of ISF A40 trended higher in
APP/PS1; aLrp1/ mice, likely due to impaired A clearance
resulting from deletion of astrocytic LRP1 (Fig. 5A). To directly
measure the elimination rate of ISF A, mice were treated with a
potent -secretase inhibitor to rapidly block A production, and
ISFAwas gradually decreased in a time-dependentmanner.We
found that the half-life of ISF A40 was slightly but significantly
increased in APP/PS1; aLrp1/ mice (Fig. 5B), indicating that
deletion of LRP1 in astrocytes may impair elimination of soluble
A from the ISF. To examinewhether LRP1deletion in astrocytes
affects APP processing, the levels of full-length APP and APP
Figure 3. Astrocytic LRP1 deletion in APP/PS1; aLrp1/mice. Astrocyte-specific LRP1-KO mice were generated by crossing the Lrp1flox/flox mice with GFAP-Cre mice, and further bred into an
APP/PS1 background. A, Adult astrocytes were established from APP/PS1 and APP/PS1; aLrp1/mice (2–3months of age). The astrocytes were costained with a rabbit anti-LRP1 antibody and
a mouse anti-GFAP antibody. Scale bar, 50m. B, Brain LRP1 and apoE levels in the cortex (n 9/group) and hippocampus (n 6–10/group) of APP/PS1 and APP/PS1; aLrp1/mice were
quantified by Western blot analysis. Data are mean SEM. **p 0.01. C, Cortical and hippocampal slides from control APP/PS1 and APP/PS1; aLrp1/ mice were costained with an LRP1
antibody and a neuronal marker anti-NeuN or an astrocytemarker anti-GFAP, respectively. Scale bar, 50m. The colocalization of the immunoreactivities of LRP1 and GFAP is abundant in sections
from APP/PS1 mice but minimum in those from APP/PS1; aLrp1/mice. Colocalization with neuronal marker NeuN was not affected by astrocytic LRP1 deletion.
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processing products in both APP/PS1 and APP/PS1; aLrp1/
mice were analyzed. No significant differences were observed be-
tween the respective amounts of full-length APP (Fig. 5C) and
soluble forms of APP (sAPP and sAPP; Fig. 5D) in 12-month-
old APP/PS1 and APP/PS1; aLrp1/mice, suggesting that LRP1
expression does not significantly affect APP processing in these
mice. In addition, previous study showed that deficiency of water
channel reduces LRP1 levels in astrocytes and exacerbates brain
A plaque deposits (Xu et al., 2015). We thus examined whether
LRP1 deficiency affects AQP-4 expression. We found that dele-
tion of astrocytic LRP1 did not significantly affect AQP-4 level in
APP/PS1; aLrp1/mice compared with littermate control mice
at 12 months of age (Fig. 5E).
LRP1 deletion in astrocytes enhances neuroinflammation in
amyloid model mice
Given chronic brain inflammatory processes, mediated by the pro-
gressive activation of astrocytes and microglia with subsequent ac-
cumulation of proinflammatory cytokines, have been shown to
contribute to AD pathogenesis (Wyss-Coray, 2006; Morales et al.,
2014), we evaluated the inflammatory status in our astrocytic LRP1
knock-out amyloid mouse model. To examine the extent of astro-
gliosis in themice, we immunostained brain sections obtained from
APP/PS1;aLrp1/andAPP/PS1micewithananti-GFAPantibody.
Quantification of GFAP immunostaining clearly demonstrated
increased activation of astrocytes in the
brains of APP/PS1; aLrp1/ mice com-
pared with those of APP/PS1 mice at 12
months of age (Fig. 6A–C). The brain sec-
tions were also immunostained with anti-
Iba1 antibody to examine the extent of
microgliosis; dystrophic microglial reactiv-
ity was more evident in APP/PS1; aLrp1/
mice (Fig. 6D–F).Westernblot analysis also
confirmed that GFAP was significantly up-
regulated in APP/PS1; aLrp1/ mice (Fig.
6G). LRP1deficiency in astrocytes in the ab-
sence ofAPP/PS1backgrounddidnot affect
GFAP levels, indicating that the increased
astrogliosis was attributed to an increase in
A accumulation and amyloid deposition
in APP/PS1; aLrp1/ mice (Fig. 6H). In
addition, LRP1 deficiency in astrocytes led
to an increase of TNF- and interleukin-1
(Fig. 6I), important proinflammatory me-
diators involved in the development of
AD (Morales et al., 2014). These findings
demonstrate deletion of astrocytic LRP1
promotes increased neuroinflammation to-
gether with amyloid deposition.
Discussion
The link between impaired Ametabolism
and AD continues to be intensely investi-
gated; however, the role of astrocytes in A
production and clearance has not been fully
elucidated. A accumulation in the brain, a
result of an imbalance of its production and
clearance, has been shown to trigger a
pathogenic cascade (Hardy and Selkoe,
2002; Blennow et al., 2006; Zheng and Koo,
2011). Given that impaired clearance of A
is a major event in late-onset AD (Mawue-
nyegaet al., 2010),whichaffects thevastma-
jority of AD patients (Alzheimer’sAssociation, 2015), improved
understanding of the pathways regulating A clearancemay help to
establish new targets for therapy and prevention. In this study, we
sought toexamine themolecularmechanismsof astrocyte-mediated
Ametabolism in vivo. We found that LRP1 in primary astrocytes
mediates the uptake and degradation of A and regulates the levels
of A-degrading enzymes. Our in vivo work using conditional
knock-out mouse models deleting LRP1 in astrocytes in the back-
ground of amyloidmodel revealed a clear role of astrocytic LRP1 in
brainA clearance impactingboth amyloidpathology andneuroin-
flammation. Our findings demonstrate a critical role of LRP1 in
astrocyte-mediated A clearance in AD pathogenesis.
A is cleared in the brain by multiple pathways, including
intracellular degradation by various brain cell types, and extra-
cellular degradation by A-degrading enzymes (Bu, 2009). Upon
cellular A internalization, the majority of A is quickly deliv-
ered to lysosomes and efficiently degraded (Mandrekar et al.,
2009; Li et al., 2012). LRP1 is characterized by its rapid enocytotic
ability tomediate cellular uptake of a variety of ligands, including
apoE,2-macroglobulin, and tissue plasminogen activator (Herz
and Strickland, 2001; Bu, 2009). Although it is controversial
whether LRP1 can directly bind to A (Sagare et al., 2007;
Yamada et al., 2008), LRP1 clearly regulates the endocytosis of
A, albeit with a slower kinetics compared with that of another
Figure 4. LRP1 deficiency in astrocytes enhances amyloid deposition in APP/PS1 mice. A, Brain sections obtained from 12-
month-old APP/PS1 and APP/PS1; aLrp1/micewere immunostained for A. Scale bar, 1mm. The percentage of area covered
by amyloid plaques was quantified. B, C, Cortical and hippocampal brain tissues were fractionated into TBS-soluble, detergent-
soluble (TBSX), and insoluble (guanidine-HCl, GDN) fractions. A levels from each fraction were quantified by ELISA. Data are
mean SEM (n 9 or 10/group). *p 0.05 (two-tailed Student’s t test). **p 0.01 (two-tailed Student’s t test).
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LRP1 ligandRAP (Kanekiyo et al., 2011). Using a strain of GFAP-
Cre mice that express Cre early in neurogenesis with the expec-
tation to delete LRP1 in both neurons and glial cells, a previous
study showed that reduced LRP1 expression in the hippocampal
neurons by50% results in early lethality inmice with no signif-
icant impact on plaque deposition (Xu et al., 2012). Utilization of
the GFAP-Cre mice here (Bajenaru et al., 2002), this resulted in
deletion of LRP1 in GFAP-positive astrocytes but not in NeuN-
positive neurons. The discrepancy might be due to differences in
Cre mouse strains, gene knock-out specificity, or efficiency. By
breeding Lrp1 floxed mice with calcium/calmodulin-dependent
protein kinase II (CaMKII-Cre) mice, our previous study
showed that LRP1 depletion in adult forebrain neurons impairs
A clearance (Kanekiyo et al., 2013). However, the role of astro-
cytic LRP1 in A metabolism in vivo has not been specifically
addressed. Several in vitro studies have implicated an important
role of astrocytes in cellular Ametabolism. When transcription
factor EBwas overexpressed in astrocytes using adeno-associated
virus-mediated gene delivery method in the hippocampus of
APP/PS1 mice, A clearance was facilitated by enhancing lyso-
some biogenesis, resulting in reduced amyloid plaque load (Xiao
et al., 2014). In human glioblastoma cells, A42 is shown to be
internalized through fluid phase macropinocytosis, transported
to lysosomes, and subjected to proteolysis, where LRP1 mediates
the uptake of soluble A42 more efficiently than that of A42
aggregates (Li et al., 2014). RAP, an antagonist of the LDLR fam-
ily members, effectively blocks astrocyte-mediated A degrada-
tion in brain sections from amyloid model mice (Koistinaho et
al., 2004).We found that deletion of LRP1 in astrocytes disturbed
ISF A clearance and increased the levels of soluble A as well as
insoluble A in the brains of APP/PS1 mice. Although further
studies are needed, LRP1 in astrocytes likely plays a critical role in
the clearance of both soluble and insoluble A.
ApoE is a critical LRP1 ligand, which significantly contributes
to A pathology in AD pathogenesis (Bu, 2009; Liu et al., 2013;
Hu et al., 2015).Deficiency of apoE significantly facilitates ISFA
clearance in PDAPP mice (DeMattos et al., 2004). Furthermore,
anti-apoE immunotherapy also ameliorates A accumulation in
APP/PS1 mice (Kim et al., 2012). Although multiple pathways
might be involved in the mechanisms, apoE has been shown to
compete with soluble A for LRP1-dependent cellular uptake in
astrocytes (Verghese et al., 2013). Thus, endogenous apoE may
compromise extracellular metabolism of soluble A by blocking
the astrocytic LRP1-mediated pathways. A recent study also
showed that the phagocytic capacity of astrocytes is highly depen-
dent on APOE isoforms (Chung et al., 2016). Whether LRP1
mediates apoE-regulated phagocytic capacity of astrocytes in
synaptic pruning, and degradation of neuronal debris and amy-
loid warrants further investigation.
Previous studies suggest that LRP1 modulates APP endocytic
trafficking,which influencesAproduction invarious cellularmod-
els (Ulery et al., 2000; Cam et al., 2005). In addition, recent in vivo
studies demonstrated that LRP1 plays an important role in modu-
lating A clearance. For instance, deletion of LRP1 in neurons or
vascularmural cells suppresses A clearance inAPP/PS1micewith-
out affecting APP processing (Kanekiyo et al., 2012, 2013). Also,
LRP1 mediates A clearance across the blood–brain barrier (Ra-
manathan et al., 2015). These studies suggest that LRP1may exhibit
differential functions in regulating A metabolism depending on
cell types and the model systems. Astrocytes represent a major cell
type mediating the elimination of A in the brain. In our present
study, deficiency of LRP1 in astrocytes disturbed A clearance, sug-
gesting that the effect of LRP1 on A clearance may be dominant
over its potentially minor role in A production in astrocytes. To-
gether, these studies establish a critical role ofLRP1 indifferentbrain
cell types in brain A clearance.
Figure 5. LRP1 deficiency in astrocytes impairs A clearance but not A production in vivo. A, B, Ametabolism in the hippocampus of APP/PS1 and APP/PS1; aLrp1/mice (n 4/group)
at the age of 3–4 months was analyzed by in vivo microdialysis. A, Baseline A40 levels were measured. To assess A40 half-life, the mice were treated with a -secretase inhibitor, and the
hippocampal ISF A40 concentrations were monitored. B, The common logarithm of percentage baseline ISF A40 concentrations versus time was plotted. Themean ISF A elimination half-life
(t1/2) was calculated for each mouse as the slope of the individual linear regressions from log (% ISF A40) versus time. Data are mean SEM. *p 0.05 (two-tailed Student’s t test). C, D,
Full-length APP (C) and sAPP and sAPP levels (D) in the hippocampus and cortex of APP/PS1 and APP/PS1; aLrp1/mice (n 8–10/group) at 12 months of age were analyzed byWestern
blotting and quantified. Data are mean SEM. E, AQP-4 in the cortex of APP/PS1 and APP/PS1; aLrp1/mice (n 8–10/group) at 12 months of age were analyzed by Western blotting and
quantified. Data are mean SEM.
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Several A degrading enzymes are abundantly expressed in
astrocytes (Mulder et al., 2012). In addition to cellular A clear-
ance, extracellular proteolytic degradation of A mediated by
enzymes, such as neprilysin, IDE, and MMPs, also represents an
important pathway in A metabolism (Saido and Leissring,
2012). LRP1 plays an important role in regulating MMP expres-
sion and functions (Etique et al., 2013). Hepatic LRP1 was sug-
gested to facilitate A degradation via various A-degrading
enzymes (Dries et al., 2012). Postmortem AD cortical brain tis-
sues exhibit decreased levels of both LRP1 and IDE compared
with those of normal aging or pathological aging individuals
(Shinohara et al., 2014). In addition, IDE-mediated degradation
of A is regulated by astrocytic apoE, a ligand for LRP1 (Jiang et
al., 2008). Here, we found that knockdown of LRP1 resulted in
reduced mRNA levels of IDE, MMP2, and MMP9 in primary
astrocytes. Although further studies are needed to determine the
molecularmechanisms underlying the interaction between LRP1
and the regulation of these enzymes, LRP1 may prevent A de-
position by facilitating cellular A uptake and enzymatic A deg-
radation in astrocytes.
Given accumulating evidence revealing the contribution of
cerebrovascular damage to AD pathogenesis (Zlokovic, 2011;
Nelson et al., 2016), and that end-feet of astrocytes surround
cerebrovasculature to maintain blood–brain barrier integrity
(Osborn et al., 2016), future studies investigating the role of as-
trocytic LRP1 in cerebrovascular A clearancemay bewarranted.
For example, thewater channel AQP-4, predominantly expressed
in the end-feet of astrocytes, regulates A accumulation, cerebral
amyloid angiopathy, and synapses in APP/PS1 mice (Xu et al.,
2015). Of note, deletion of AQP-4 has been shown to increase
astrocyte atrophy and suppresses LRP1 expression in the astro-
cytes surrounding A plaques (Yang et al., 2012; Xu et al., 2015).
Our results showed that deletion of LRP1 in the astrocytes did not
significantly alter the levels of AQP-4, suggesting that AQP-4may
function in the upstream of LRP1 in astrocytes. However, we
cannot rule out the possibility that astrocytic LRP1 and AQP-4
function cooperatively in mediating ISF A clearance along the
cerebrovasculature drainage pathway. Future studies are needed
to understand whether LRP1 and AQP-4 exhibit a functional
interaction and whether upregulation of LRP1 expression and/or
function in astrocytes can rescue the deficits of A metabolism
resulted from AQP-4 deficiency.
In conclusion, we demonstrate the significant contribution of
astrocytic LRP1 to Ametabolism using both in vitro and in vivo
models, thereby expanding upon recent findings of LRP1’s criti-
cal role in neurons (Kanekiyo et al., 2013), vascular mural cells
(Kanekiyo et al., 2012), and endothelial cells (Storck et al., 2016).
Astrocytic LRP1 deficiency results in impaired ISF A elimina-
Figure 6. LRP1 deficiency in astrocytes leads to an increase in neuroinflammation.A–C, Brain sections fromAPP/PS1 and APP/PS1; aLrp1/mice (n 8 or 9/group) at 12months of agewere
immunostained for the astrocytemarker GFAP (A) andquantified (C). Scale bar, 1mm.B, Higher-magnification images for GFAP immunostaining in the cortex andhippocampus. Scale bar, 200m.
Data aremean SEM. *p 0.05.D–F, Brain sections from APP/PS1 and APP/PS1; aLrp1/mice (n 8 or 9/group) were immunostained for themicroglia marker Iba1 (D) and quantified (F ).
Scale bar, 1mm.E, Higher-magnification images for Iba1 immunostaining in the cortex andhippocampus. Scale bar, 200m.Data aremean SEM. *p0.05 (two-tailed Student’s t test). **p
0.01 (two-tailed Student’s t test). G, GFAP in the cortex (n 9/group) of APP/PS1 and APP/PS1; aLrp1/mice examined byWestern blotting. Data are mean SEM. *p 0.05.H, GFAP in the
cortex (n 8 or 9/group) of control and aLrp1/mice (in the absence of APP/PS1 background) examined byWestern blotting. Data aremean SEM. I, TNF- and interleukin-1 (IL-1) in the
cortex of APP/PS1 and APP/PS1; aLrp1/mice (n 9/group) evaluated by real-time PCR. Data are mean SEM. *p 0.05 (two-tailed Student’s t test).
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tion and aggravated A deposition in the brains of APP/PS1
mice; the suppression of both astrocytic intracellular degradation
and extracellular clearance of A viaAdegrading enzymes likely
mediates these effects. Given that LRP1 levels are shown to be
decreased in ADbrains comparedwith control individuals (Kang
et al., 2000), restoring LRP1 expression and functions could be an
effective strategy to facilitate A clearance and counter amyloid
pathology in AD. Future studies designed to develop pharmaco-
logical approaches and gene therapies targeting astrocytic LRP1
may hold promises as means to combat AD.
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